Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m

Executive Summary

With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.

You may also be interested in...

Biogen Claims Lead Among Adalimumab Biosimilars In Europe

With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.

Imraldi sets pace on German price cuts

Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.

Biogen says sales will slow but lauds supply

Biogen has warned that sales growth for its biosimilars is likely to slow in the second half of 2018, with pricing pressure projected to outweigh volume growth. Nevertheless, the US-based firm believes that the strength of its supply chain will help it maintain a “competitive advantage”, in an increasingly burgeoning market, as Biogen also eyes introducing one of the first Humira (adalimumab) biosimilars in the fourth quarter.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts